311 related articles for article (PubMed ID: 1830033)
1. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
3. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
[TBL] [Abstract][Full Text] [Related]
4. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled monoclonal antibody 15 and its fragments for localization and imaging of xenografts of human lung cancer.
Endo K; Kamma H; Ogata T
J Natl Cancer Inst; 1988 Aug; 80(11):835-42. PubMed ID: 3392743
[TBL] [Abstract][Full Text] [Related]
6. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.
Hirsch R; Bluestone JA; DeNenno L; Gress RE
Transplantation; 1990 Jun; 49(6):1117-23. PubMed ID: 2141740
[TBL] [Abstract][Full Text] [Related]
8. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.
Vogel CA; Bischof-Delaloye A; Mach JP; Pèlegrin A; Hardman N; Delaloye B; Buchegger F
Br J Cancer; 1993 Oct; 68(4):684-90. PubMed ID: 8398694
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen.
van Dijk J; Warnaar SO; van Eendenburg JD; Thienpont M; Braakman E; Boot JH; Fleuren GJ; Bolhuis RL
Int J Cancer; 1989 Feb; 43(2):344-9. PubMed ID: 2521843
[TBL] [Abstract][Full Text] [Related]
12. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
14. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
[TBL] [Abstract][Full Text] [Related]
15. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
16. Augmentation by bispecific F(ab')2 reactive with P-glycoprotein and CD3 of cytotoxicity of human effector cells on P-glycoprotein positive human renal cancer cells.
Heike Y; Okumura K; Tsuruo T
Jpn J Cancer Res; 1992 Apr; 83(4):366-72. PubMed ID: 1354668
[TBL] [Abstract][Full Text] [Related]
17. Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
Colapinto EV; Humphrey PA; Zalutsky MR; Groothuis DR; Friedman HS; de Tribolet N; Carrel S; Bigner DD
Cancer Res; 1988 Oct; 48(20):5701-7. PubMed ID: 3167830
[TBL] [Abstract][Full Text] [Related]
18. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts.
Kranenborg MH; Boerman OC; de Weijert MC; Oosterwijk-Wakka JC; Corstens FH; Oosterwijk E
Cancer; 1997 Dec; 80(12 Suppl):2390-7. PubMed ID: 9406688
[TBL] [Abstract][Full Text] [Related]
19. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
20. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
